Oxford Nanopore Technologies PLC (ONT) AI Stock Analysis

• Market Cap: £1.20B
• Dividend Yield: N/A
• Average Volume (3M): 1.51M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: 22.03%
• EPS Growth: 20.01%
• Country: UK
• Employees: 1,382
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 965,866,330
• 10 Day Avg. Volume: 1,415,809
• 30 Day Avg. Volume: 1,510,061
• PEG Ratio: 0.50
• Price to Book (P/B): 1.97
• Price to Sales (P/S): 6.31
• P/FCF Ratio: -9.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £191.00
• Price Target Upside: 50.75% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: 128.00p ▲(1.03% Upside)

The overall stock score of 51 reflects a combination of financial challenges and technical weaknesses, offset by positive earnings guidance and corporate governance initiatives. The company's revenue growth and strategic focus on improving profitability are promising, but current financial and market conditions pose significant risks.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, supporting long-term business expansion and stability.

Strong Equity Position

A strong equity position enhances financial stability and provides a buffer against economic uncertainties, supporting sustainable growth.

Operational Efficiency

Improved operational efficiency and cost management strategies are expected to enhance profitability and competitive positioning.

Negative Factors

Negative Cash Flow

Persistent negative cash flow can limit investment in growth initiatives and strain financial resources, impacting long-term viability.

Unprofitability

Ongoing unprofitability indicates challenges in cost management and achieving sustainable margins, which may hinder future growth.

Challenges in China

Market challenges in China could limit growth opportunities in a key region, affecting overall revenue potential and strategic expansion.

Oxford Nanopore Technologies PLC Business Overview & Revenue Model

Company Description

Oxford Nanopore Technologies PLC (ONT) is a biotechnology company specializing in the development and commercialization of innovative nanopore-based sequencing technology. Founded in 2005 and headquartered in Oxford, UK, ONT operates in the life sciences sector, primarily focusing on genomic research, clinical diagnostics, and environmental monitoring. The company's core products include portable DNA and RNA sequencing devices such as the MinION, Flongle, and PromethION, which enable real-time, high-throughput sequencing for a variety of applications across academic, clinical, and industrial markets.

How the Company Makes Money

Oxford Nanopore Technologies generates revenue primarily through the sale of its sequencing devices, consumables, and associated software. The company's revenue model encompasses multiple streams, including direct sales of hardware, ongoing consumable sales, and support services for its sequencing platforms. Additionally, ONT licenses its technology and provides collaborative services for research and development projects. Significant partnerships with academic institutions, healthcare organizations, and pharmaceutical companies enhance its earnings by expanding its customer base and facilitating the adoption of its sequencing technology in various fields. The company also benefits from grants and funding aimed at advancing genomic research and innovation.

Oxford Nanopore Technologies PLC Financial Statement Overview

Summary

Oxford Nanopore Technologies PLC demonstrates revenue growth and a strong equity position, crucial for long-term sustainability. Nonetheless, persistent losses and negative cash flows highlight profitability and cash management challenges that require strategic attention to improve financial health.

Income Statement

Oxford Nanopore Technologies PLC shows a consistent revenue growth trend, with a 7.95% increase from 2023 to 2024. However, the company remains unprofitable, reflected by negative EBIT and net income margins, indicating ongoing challenges in cost management and profitability.

Balance Sheet

The company maintains a solid equity base with an equity ratio of 79.03% in 2024, suggesting financial stability. However, the high debt-to-equity ratio of 0.08 indicates potential leverage concerns, although manageable due to strong equity.

Cash Flow

Operating cash flow remains negative, highlighting cash management challenges. Despite an improvement in free cash flow to net income ratio, free cash flow remains negative, suggesting ongoing cash flow constraints that may impact future growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	151.91M	183.19M	169.67M	198.60M	133.66M	113.86M
Gross Profit	86.63M	105.39M	90.48M	123.81M	73.19M	46.88M
EBITDA	-101.49M	-93.09M	-105.71M	-49.67M	-140.34M	-55.07M
Net Income	-107.44M	-146.19M	-154.51M	-91.03M	-167.61M	-61.24M
Balance Sheet
Total Assets	671.70M	742.05M	777.06M	823.89M	841.87M	281.21M
Cash, Cash Equivalents and Short-Term Investments	331.80M	338.37M	270.05M	476.19M	618.47M	80.86M
Total Debt	44.10M	45.96M	41.66M	34.10M	24.80M	23.63M
Total Liabilities	148.30M	155.71M	133.21M	130.33M	137.89M	95.28M
Stockholders Equity	523.40M	586.34M	643.85M	693.56M	703.98M	185.93M
Cash Flow
Free Cash Flow	-84.45M	-123.83M	-164.59M	-91.62M	-84.64M	-90.28M
Operating Cash Flow	-74.11M	-109.89M	-137.30M	-49.39M	-53.83M	-63.81M
Investing Cash Flow	50.76M	15.03M	-61.79M	-65.79M	-161.99M	-26.94M
Financing Cash Flow	72.15M	73.58M	64.73M	-13.71M	622.90M	158.58M

Oxford Nanopore Technologies PLC Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 126.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ONT, the sentiment is Negative. The current price of 126.7 is below the 20-day moving average (MA) of 131.49, below the 50-day MA of 134.90, and below the 200-day MA of 142.63, indicating a bearish trend. The MACD of -3.09 indicates Positive momentum. The RSI at 44.39 is Neutral, neither overbought nor oversold. The STOCH value of 15.80 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:ONT.

Oxford Nanopore Technologies PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OXB	56 Neutral	£707.56M	-16.70	-74.64%	―	55.44%	75.77%
PRTC	55 Neutral	£291.47M	8.75	15.04%	―	1231.50%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONT	51 Neutral	£1.20B	-8.39	-26.01%	―	22.03%	20.01%
SCLP	46 Neutral	£105.85M	-7.73	―	―	―	-94.12%
AVCT	42 Neutral	£312.07M	―	―	―	―	―
4BB	41 Neutral	£100.65M	-6.54	-209.34%	―	198.49%	-26.66%

Oxford Nanopore Technologies PLC Corporate Events

Oxford Nanopore Expands Share Capital with New Equity Issuance

Oxford Nanopore Technologies PLC announced the issuance of 381,797 ordinary shares following the exercise of options and remuneration schemes, which have been admitted to trading on the London Stock Exchange. This increases the company’s issued share capital to 965,866,329 ordinary shares, impacting shareholder voting rights and potentially influencing market perceptions of the company’s growth and financial strategies.

Oxford Nanopore Technologies to Engage in December Investor Conferences

Oxford Nanopore Technologies announced its participation in several investor conferences in December, including the Citi 2025 Global Healthcare Conference, the 37th Annual Piper Sandler Healthcare Conference, and the Berenberg European Conference. These events will feature analyst-led discussions and investor meetings, providing the company an opportunity to engage with stakeholders and potentially strengthen its market position.

Oxford Nanopore Technologies Announces Share Incentive Plan Transaction

Oxford Nanopore Technologies PLC announced a transaction under its Share Incentive Plan (SIP) involving Nick Keher, the company’s Chief Financial Officer. On 12 November 2025, Keher was awarded 104 Partnership Shares, purchased at £1.44 each, and 104 Matching Shares, issued at no cost, as part of the company’s efforts to align employee interests with corporate performance. This transaction, conducted on the London Stock Exchange, reflects the company’s commitment to incentivizing its management team and could enhance stakeholder confidence in the company’s governance practices.

Oxford Nanopore Delays Investor Event Amid CEO Transition, Reaffirms Revenue Guidance

Oxford Nanopore Technologies has postponed its virtual investor event due to the ongoing CEO succession process, while reaffirming its full-year 2025 revenue growth guidance at the top end of 20-23%. This decision reflects the company’s strategic focus on leadership transition while maintaining strong financial performance expectations, which may reassure stakeholders about its stability and future direction.

Oxford Nanopore Expands Share Capital with New Equity Issue

Oxford Nanopore Technologies PLC announced the issuance of 1,704,751 ordinary shares following the exercise of options and remuneration schemes, which are now listed on the London Stock Exchange. This increases the company’s total voting rights to 965,484,532, impacting shareholder calculations under FCA rules.

Oxford Nanopore Technologies to Host Investor Event and Participate in Conferences

Oxford Nanopore Technologies has announced an investor event on November 14, 2025, to discuss its commercial strategy and growth opportunities. Additionally, the company will participate in the J.P. Morgan UK Leaders Conference and the Jefferies Global Healthcare Conference in November, offering presentations and meetings with investors. These events aim to enhance investor understanding of the company’s market potential and strategic direction.

Oxford Nanopore Technologies Announces Share Incentive Plan Transaction

Oxford Nanopore Technologies PLC announced a transaction involving the Share Incentive Plan (SIP) where 100 ordinary shares were awarded to Nick Keher, the company’s Chief Financial Officer, as part of the SIP. This transaction, which took place on 14 October 2025, involved the purchase of shares using the employee’s gross salary and the issuance of matching shares by the company, reflecting its commitment to employee investment and engagement.

Oxford Nanopore Expands Share Capital with New Equity Issue

Oxford Nanopore Technologies PLC has announced the issuance of 630,273 ordinary shares following the exercise of options and remuneration schemes, which have been admitted to the FCA’s Official List and the London Stock Exchange. This increases the company’s total issued share capital to 963,779,781 shares, providing a new denominator for shareholders to calculate their interests under the FCA’s rules.

Oxford Nanopore Technologies Issues Shares Under SIP for CFO

Oxford Nanopore Technologies PLC announced the issuance of Partnership Shares and Matching Shares under its Share Incentive Plan (SIP) for Nick Keher, the company’s Chief Financial Officer. The transaction involved the purchase of 89 ordinary shares at £1.69 each, matched by an equal number of shares issued by the company, reflecting its commitment to employee participation in ownership and aligning managerial interests with shareholder value.